Author

Adam Rosenthal

Observed name: A.E. Rosenthal

Institution: Cancer Research And Biostatistics

Observed institutions: Harvard University, Cancer Research And Biostatistics

ORCID: 0009-0001-3531-6043

Observed ORCID: 0009-0001-3531-6043

OpenAlex ID: A5111069250

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al. · Clinical Cancer Research · 24

Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy

2025 · Hillary S Andrews, Nevine Zariffa, et al. · Journal for ImmunoTherapy of Cancer · 6

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

2025 · Terri L. Parker, Adam Rosenthal, et al. · Blood · 5

Use of Circulating Tumor DNA in Oncology

2025 · Emily Goren, Katie Nishimura, et al. · Chapman & Hall/CRC eBooks

SWOG Statistical Calculators for Design and Analysis of Clinical Trials

2025 · Adam Rosenthal, Rachael Sexton, et al. · Chapman & Hall/CRC eBooks

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

2025 · Sikander Ailawadhi, Divaya Bhutani, et al. · Blood

Data from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Table S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S4 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S3 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S6 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Supplementary Figure S2 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

2025 · Hillary S. Andrews, Nevine Zariffa, et al.

Adjuvant Treatment and Outcomes for Stage III Serous Endometrial Cancer Patients at a Single Institution

2024 · N. Posever, A.E. Rosenthal, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 15

Citation count: 35

H-index: 3

I10-index: 1